The objective of this study is to assess the safety and effectiveness of the Cordis Bilateral AAA device and its Delivery System compared to open surgical repair for the treatment of Abdominal Aortic Aneurysm (AAA).

Primary success is defined as freedom from all of the following: rupture of aneurysm, enlargement of aneurysm > 0.5 cm on CT scan, with or without endoleak, as compared to any previous measurement, symptomatic aneurysm requiring treatment.

The absence of major complications at thirty days defined as arterial thrombosis, respiratory impairment, renal failure, myocardial infarction (M.I.) and stroke in combination with the absence of major complications at one year.

Secondary Outcome Measures:

· Technical success defined as the successful access and deployment of the device at the appropriate anatomic location with aneurysmal exclusion determined by angiography at the time of deployment.

·

Estimated Enrollment:

29

Study Start Date:

December 1999

Estimated Study Completion Date:

February 2006

Eligibility

Ages Eligible for Study:

40 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

- Anatomic (stent-graft)

Aortic Aneurysm Diameter

> 4.5 cm

Those aortic aneurysms < 4.5 cm that are at least 1.5 times the diameter of the aorta with a size increase of 5 mm or greater over a six month period will also be included for possible treatment.

Aorto-iliac aneurysms in which the aortic aneurysm is < 4.5 cm but the iliac artery aneurysms are > 3.0 cm in diameter or there is evidence of recent expansion (5 mm or greater over a six month period) in iliac aneurysms < 3.0 cm.

*NOTE: An aortic diameter cannot be treated if the iliac diameter is not in the same range (e.g. 26-28 mm aortic necks must be in conjunction with 13-18 mm common iliacs).

Anatomic (surgical controls)

· Surgical controls will be required to meet only the aortic or aorto-iliac aneurysm size requirements for anatomic inclusion criteria.

Aortic Aneurysm Diameter

> 4.5 cm

Those aortic aneurysms <4.5 cm that are at least 1.5 times the diameter of the aorta with a size increase of 5 mm or greater over a six month period will also be included for possible treatment.

Aorto-iliac aneurysm in which the aortic aneurysm is <4.5 cm but the iliac artery aneurysm are >3.0 cm in diameter or there is evidence of recent expansion (5 mm or greater over a six month period) in iliac aneurysms <3.0 cm.

Saccular aortic aneurysms > 3.0 cm.

Clinical (stent-graft)

Males and non-pregnant females > 40 years of age.

Clinical (surgical controls)

Surgical control patients will be required to meet all of the above-stated stent-graft clinical inclusion criteria.

Exclusion Criteria:

Anatomic (stent-graft)

Aortic Aneurysm Diameter

· < 4.5 cm that are not at least 1.5 times the diameter of the aorta with evidence of a size increase of 5 mm or greater within a six month period.

Aorto-iliac Aneurysms

< 3.0 cm in diameter unless evidence of recent expansion (5 mm or greater within a six month period).

The iliac portion of the aneurysm extending to the bifurcation bilaterally which would necessitate covering both internal iliac arteries with the device.

Aortic Neck

Diameter < 17 mm and > 28 mm (Phase I)

Diameter < 14 and >28 (Phase II)

Thrombus lined

Highly calcified

NOTE: See inclusion criteria for length below the renals and degree of angulation.

· Surgical controls will be excluded based only on the aortic or aorto-iliac aneurysm size requirements for anatomic exclusion criteria.

Aortic Aneurysm Diameter

· < 4.5 cm that are not at least 1.5 times the diameter of the aorta with evidence of a size increase of 5 mm or greater within a six month period.

Aorto-Iliac Aneurysms

< 3.0 cm in diameter unless evidence of recent expansion (5 mm or greater within a six month period).

The iliac portion of the aneurysm extending to the bifurcation bilaterally which would necessitate surgically covering both internal iliac arteries.

Clinical (stent-graft)

Ruptured abdominal aortic aneurysm.

Renal insufficiency – creatinine level > 2.5 mg/dl.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00235118